A 19-month-old boy with fever and lymphadenopathy

All children included in the analysis achieved swallowing, oral nutrition, and airway protection outcomes.

Recent data revealed a 110% increase in speech disorder diagnoses for children aged 0 to 12 years in 2022, compared to the pre-pandemic era.

In identical phase 3 trials, roflumilast demonstrated topline positive results, reducing itch in children and adults with mild to moderate AD.

As little as 39 minutes less sleep per night for 1 week can have an impact on the quality of life of children.